To the Editor, {#s1a}
==============

Mutations in the *CEBPA*gene occur in 7%-15% of all acute myeloid leukemia (AML) patients \[[@ref1],[@ref2]\]. However, we found that the frequency of such mutation may be high in Chinese AML patients \[[@ref3],[@ref4]\]. Although AML with *CEBPA* double mutations *(CEBPA*^dm^*)* indicates a favorable outcome, recent data show that more than 50% of patients finally relapsed when consolidated with chemotherapy alone \[[@ref5]\]. Clonal evolution (CE) is an important factor for relapse \[[@ref6]\]. However, studies discussing CE in AML patients with *CEBPA*^dm^ are limited \[[@ref7],[@ref8]\]. Here, we report CE in two patients with *CEBPA*^dm^ determined by sensitive next-generation sequencing (NGS).

Two female AML patients were diagnosed in our hospital in January 2012 and September 2013. Standard '3+7' induction chemotherapy was administered. Both of them achieved CR after induction therapy. Patient 1 received consolidation therapy with one course of DA (daunorubicin + cytarabine), four courses of high-dose cytarabine (HD-Ara-C), and one course of DA. Patient 2 received consolidation therapy with three courses of HD-Ara-C and two courses of immunotherapy. After long-term remissions (63 and 40 months), they both relapsed. Cytogenetic and fusion gene analyses indicated no difference from diagnosis. NGS analysis indicated altered mutations sites of the *CEBPA* gene in Patient 2 ([Figure 1](#f1){ref-type="fig"}). New co-occurring mutations emerged at relapse: *SETD2* mutation in Patient 1 and *WT1* mutation in Patient 2 ([Table 1](#t1){ref-type="table"}). After relapse, Patient 1 achieved CR with a DA regimen and Patient 2 refused treatment.

The first report for CE in patients with *CEBPA*^dm^ included two patients \[[@ref7]\]. In the first patient, the amino-terminal frame-shift mutation was duplicated and found on both alleles at relapse. In the second patient, the amino-terminal frame-shift mutation and a mutation in the fork region were found either alone or combined on the same allele, suggesting a subclone formation \[[@ref7]\]. Another study reported CE in 22 patients; two of them lost mutations and none acquired new mutation at relapse \[[@ref8]\]. Twenty patients harboring *CEBPA* mutations relapsed with identical mutation patterns; three of them had a second relapse that also exhibited the same patterns as their initial diagnosis and first relapse \[[@ref8]\]. Two patients had concomitant *FLT3*-ITD mutations at diagnosis and one was lost at relapse. Two patients acquired *FLT3*-TKD mutations at relapse. N-RAS mutations were detected in three patients at diagnosis and two of them retained the identical mutation at relapse \[[@ref8]\]. In this case report, we found mutation site alteration in the *CEBPA* gene and two newly emerged co-occurring mutations.

CE of patients with *CEBPA*^dm^ can be summarized as follows: 1) allele alteration of *CEBPA* gene: acquire or lose mutation site in allele; 2) mutation site alteration in *CEBPA* gene: acquire or lose mutation site in *CEBPA* gene other than allele; 3) co-occurring mutation alteration: acquire or lose co-occurring mutation. One issue that needs to be resolved is the relationship between time and CE after CR. In this case report, these two patients relapsed after long-term remissions, and new co-occurring mutations emerged in both of them. Hence, whether late relapse is associated with new co-occurring mutations is unknown.
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###### *CEBPA* and co-occurring mutations at diagnosis and relapse.
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